Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 7:46 PM
Ignite Modification Date: 2025-12-24 @ 7:46 PM
NCT ID: NCT00175903
Eligibility Criteria: Inclusion Criteria: * Diagnosis of epilepsy (all types of seizures) was made during the past year * Subjects must have had at least two unprovoked seizures in the past 2 years with at least one during the last 6 months * Female subjects without childbearing potential are eligible. Female subjects with childbearing potential are eligible if they use a medically accepted contraceptive method Exclusion Criteria: * Subjects previously allocated to a trial treatment (CBZ, VPA and LEV) used in this trial * Participation in another clinical trial with an investigational drug or device within 12 weeks of the selection visit (V1), or at any time during this trial * Pregnant or lactating women * Presence of known pseudoseizures within the last year * Uncountable seizures (clusters) or history of convulsive status epilepticus * Any disorder or condition that may interfere with the absorption, distribution, metabolisation or excretion of drugs * History of suicide attempt, current suicidal ideation, or other serious psychiatric disorders requiring or having required hospitalization or medication within the previous five years * Presence of progressive cerebral disease, any other progressively degenerative neurological disease, or any cerebral tumors * Presence of a terminal illness or any medical condition that might interfere with the subject's trial participation
Healthy Volunteers: False
Sex: ALL
Minimum Age: 16 Years
Study: NCT00175903
Study Brief:
Protocol Section: NCT00175903